Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab for Chronic Active Antibody-Mediated Rejection in Kidney Transplant
NCT05913596Unknown
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- May 2023
- Primary completion
- Apr 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of daratumumab in antibody mediated rejection (AMR), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: The change of donor specific antibody at 6 months. Status: unknown.
02
Drugs
daratumumab
03
Conditions
antibody mediated rejection (AMR)
Beyond the preview
Go deeper on NCT05913596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05913596.